KALA BIO, Inc. (NASDAQ:KALA) Short Interest Down 18.7% in November

KALA BIO, Inc. (NASDAQ:KALA) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 30,500 shares, a drop of 18.7% from the October 31st total of 37,500 shares. Based on an average trading volume of 21,400 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.8% of the company’s shares are sold short.

KALA BIO Trading Down 1.7 %

Shares of KALA stock traded down $0.12 during mid-day trading on Monday, reaching $6.74. The company’s stock had a trading volume of 937 shares, compared to its average volume of 81,764. The company’s 50 day simple moving average is $6.17 and its 200-day simple moving average is $6.26. KALA BIO has a 12-month low of $4.21 and a 12-month high of $10.97. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 3.18. The firm has a market capitalization of $31.07 million, a PE ratio of -0.55 and a beta of -2.13.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. On average, research analysts predict that KALA BIO will post -10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of KALA BIO in a research report on Friday, November 15th. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a research note on Monday, August 19th.

Institutional Investors Weigh In On KALA BIO

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP acquired a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises about 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th largest holding. SR One Capital Management LP owned 15.76% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.